Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
Non-Small Cell Lung Cancer Pancreatic Cancer

New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer

Ulas D. Bayraktar, MD
2024-12-06
Non-Small Cell Lung Cancer

New Indication: Osimertinib after Chemoradiotherapy in NSCLC

Ulas D. Bayraktar, MD
2024-09-30
Non-Small Cell Lung Cancer

New Drug: Lazertinib for EGFR mutated NSCLC

Ulas D. Bayraktar, MD
2024-08-27
Non-Small Cell Lung Cancer

New Drug: Repotrectinib for ROS1-fusion positive NSCLC

Ulas D. Bayraktar, MD
2024-06-21
Non-Small Cell Lung Cancer

New Drug: Amivantamab for NSCLC

Ulas D. Bayraktar, MD
2024-01-13
Non-Small Cell Lung Cancer

New Indication: Perioperative Durvalumab for NSCLC

Ulas D. Bayraktar, MD
2023-11-20
Non-Small Cell Lung Cancer

New Indication: Osimertinib in First-Line NSCLC

Ulas D. Bayraktar, MD
2023-11-20
Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC

Ulas D. Bayraktar, MD
2023-09-23
Non-Small Cell Lung Cancer

New Indication: Pembrolizumab for Early-Stage NSCLC

Ulas D. Bayraktar, MD
2023-08-20
Non-Small Cell Lung Cancer

New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC

Ulas D. Bayraktar, MD
2023-08-20

Posts pagination

1 2 3
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj